Drug intelligence / Profile preview

MGT:2201

Development stage: Preclinical
Lead developer: MiGenTra

Overview

MGT:2201 is a biosimilar candidate currently in preclinical development by MiGenTra, a pharmaceutical company focused on the Middle East and Africa (MEA) region. The drug is being developed for oncology indications, although its specific molecular target and the reference biologic it is intended to replicate remain undisclosed. MGT:2201 is part of MiGenTra's 'In-House Development' portfolio, which aims to provide high-quality, affordable biologic treatments to underserved markets.

Beyond the preview

Go deeper on MGT:2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGT:2201.

Explore the full profile